Pregled bibliografske jedinice broj: 871667
Dexamethasone for adult community-acquired bacterial meningiti s: a retrospective analysis of 20 years of experience in daily practice
Dexamethasone for adult community-acquired bacterial meningiti s: a retrospective analysis of 20 years of experience in daily practice // Journal of neurology, 259 (2012), 2; 225-236 doi:10.1007/s00415-011-6150-6 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 871667 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dexamethasone for adult community-acquired bacterial meningiti s: a retrospective analysis of 20 years of experience in daily practice
(Dexamethasone for adult community-acquired bacterial meningitis : a retrospective analysis of 20 years of experience in daily practice)
Autori
Peterković, Vjerislav ; Trkulja, Vladimir ; Kutleša, Marko ; Krajinović, Vladimir ; Lepur, Dragan
Izvornik
Journal of neurology (0340-5354) 259
(2012), 2;
225-236
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
meningitis, dexamethasone
Sažetak
The aim of the study was to assess adjunctive intravenous dexamethasone in adult community-acquired bacterial meningitis (BM) in daily practice. Analysis of consecutive patients (1990–2009) with acute community-acquired bacterial meningitis in a single centre in Zagreb, Croatia, N = 304. Adjusted relative risks [RR, dexamethasone vs. no dexamethasone (control)] of Glasgow Outcome Scale (GOS) = 1 (death) and GOS = 5 (full recovery) at discharge/end of specific treatment were estimated considering demographics ; co-morbidity ; BM pathogenesis and on-admission characteristics, and cerebrospinal fluid (CSF) inflammation markers ; causative agent and antibiotic use. Two hundred forty (79%) patients had proven BM (43.1% Streptococcus pneumoniae, any other agent ≤8.2%). No independent effects of dexamethasone on GOS = 1 or GOS = 5 were observed in the entire cohort (dexamethasone n = 119, control n = 185 ; RR = 1.06, 95% CI 0.77–1.45 and RR = 0.99, CI 0.83–1.20, respectively), microbiologically proven disease (dexamethasone n = 104, control n = 136 ; RR = 0.97, CI 0.69–1.38 and RR = 1.03, CI 0.82–1.28), pneumococcal disease (dexamethasone n = 71, control n = 60 ; RR = 0.95, CI 0.53–1.70 and RR = 0.82, CI 0.57–1.18), and also in other BM, subgroups based on consciousness disturbance, CSF markers, prior use of antibiotics and timing of appropriate antibiotic treatment. CSF markers did not predict the outcomes. Our experience does not substantiate the reported benefits of adjunctive dexamethasone in adult BM. Socio-economic and methodological factors do not seem to explain this discrepancy. Empirical use of dexamethasone in this setting appears controversial.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Klinički bolnički centar Zagreb
Profili:
Vladimir Krajinović
(autor)
Marko Kutleša
(autor)
Dragan Lepur
(autor)
Vladimir Trkulja
(autor)
Vjerislav Peterković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE